177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial si...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-10-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_112_18 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045313289551872 |
|---|---|
| author | Majid Assadi Hojjat Ahmadzadehfar |
| author_facet | Majid Assadi Hojjat Ahmadzadehfar |
| author_sort | Majid Assadi |
| collection | DOAJ |
| description | Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with 177Lu-DOTATATE and 177Lu-PSMA, presumably as a first report in this regard. |
| format | Article |
| id | doaj-art-d003aaa7bf2b4dd49b43055f286c2fe9 |
| institution | DOAJ |
| issn | 1450-1147 1607-3312 |
| language | English |
| publishDate | 2019-10-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | World Journal of Nuclear Medicine |
| spelling | doaj-art-d003aaa7bf2b4dd49b43055f286c2fe92025-08-20T02:54:43ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11471607-33122019-10-01180440640810.4103/wjnm.WJNM_112_18177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatmentMajid Assadi0Hojjat Ahmadzadehfar1The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, IranDepartment of Nuclear Medicine, University Hospital Bonn, Bonn, GermanyPatients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with 177Lu-DOTATATE and 177Lu-PSMA, presumably as a first report in this regard.http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_112_18 177ludotatateprostate-specific membrane antigenradioiodine-refractory differentiated thyroid cancer |
| spellingShingle | Majid Assadi Hojjat Ahmadzadehfar 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment World Journal of Nuclear Medicine 177lu dotatate prostate-specific membrane antigen radioiodine-refractory differentiated thyroid cancer |
| title | 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment |
| title_full | 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment |
| title_fullStr | 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment |
| title_full_unstemmed | 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment |
| title_short | 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment |
| title_sort | 177lu dotatate and 177lu prostate specific membrane antigen therapy in a patient with advanced metastatic radioiodine refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment |
| topic | 177lu dotatate prostate-specific membrane antigen radioiodine-refractory differentiated thyroid cancer |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_112_18 |
| work_keys_str_mv | AT majidassadi 177ludotatateand177luprostatespecificmembraneantigentherapyinapatientwithadvancedmetastaticradioiodinerefractorydifferentiatedthyroidcancerafterfailureoftyrosinekinaseinhibitorstreatment AT hojjatahmadzadehfar 177ludotatateand177luprostatespecificmembraneantigentherapyinapatientwithadvancedmetastaticradioiodinerefractorydifferentiatedthyroidcancerafterfailureoftyrosinekinaseinhibitorstreatment |